NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA ® ...
Jazz plans to submit supplemental New Drug Application in first half of 2025 for this combination therapy as a first-line maintenance treatment for ES-SCLC DUBLIN, Oct. 15, 2024 /PRNewswire/ -- Jazz ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback